Equity Field Notes from temporal sources

[DanWebzster]

KRYS Summer/18 could be a valuation inflection point

Lead program combines a previously approved viral vector and a gene validated by clinical trial in another indication.

KRYS will begin a study 5/18 to ascertain the effectiveness of this treatment in Epidermolysis Bulbosa.

Presently, EB patients spend as much as 200K a year on bandages and dressing.

Assuming the company can treat 2100 patients @ 150K / year and 14x EBITDA, MC coud reach $4B and $ 300 pps.

The effectiveness of the treatment could be evident as early as the summer months.

ABEO also has a drug in development for EB; and, they are further along in the development process.